Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial

@article{Hirayama2015EffectOD,
  title={Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial},
  author={Yasuo Hirayama and Kunihiko Ishitani and Yasushi Sato and Satoshi Iyama and Kohichi Takada and Kazuyuki Murase and Hiroyuki Kuroda and Yasuhiro Nagamachi and Yuichi Konuma and Akihito Fujimi and Tamotsu Sagawa and Kaoru Ono and Hiroto Horiguchi and Takeshi Terui and Kazuhiko Koike and Toshiro Kusakabe and Tsutomu Sato and Rishu Takimoto and Masayoshi Kobune and Junji Kato},
  journal={International Journal of Clinical Oncology},
  year={2015},
  volume={20},
  pages={866-871}
}
Chemotherapy-induced peripheral neuropathy (CIPN) is difficult to manage. A phase III trial conducted in the United States demonstrated that duloxetine was effective for CIPN caused by taxane and platinum-based chemotherapy. No randomized trial of duloxetine for CIPN has been conducted in Japan. In this open-label, randomized, crossover study, eligible patients were randomized to Group A or Group B. Group A received duloxetine 20 mg/day orally for the first week and 40 mg/day for the next 3… CONTINUE READING

6 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Our data suggests that duloxetine has a beneficial effect on CIPN caused by oxaliplatin , paclitaxel , vincristine , or bortezomib in Japanese patients .
Our data suggests that duloxetine has a beneficial effect on CIPN caused by oxaliplatin , paclitaxel , vincristine , or bortezomib in Japanese patients .
All Topics